Full Text View
Tabular View
No Study Results Posted
Related Studies
Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration
This study has been completed.
Study NCT00220805   Information provided by Talecris Biotherapeutics
First Received: September 14, 2005   Last Updated: July 23, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Macular Degeneration
Additional conditions recognized in this trial
Choroidal Neovascularization
More general conditions related to this trial
Choroid Diseases
Eye Diseases
Metaplasia
Neovascularization, Pathologic
Pathologic Processes
Retinal Degeneration
Retinal Diseases
Uveal Diseases
Interventions listed in this trial
Albumin (Human) 25%, USP
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Talecris Biotherapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services